BioSpace News Archive

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator in Indonesia.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced details for the Company’s 2023 Investor Update conference call.

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it received additional non-dilutive funds from Radium Capital for A$973,144 for Recce’s future research and development tax incentive.

Extendicare Inc. announced that it plans to release its financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023.

BridGene Biosciences, Inc. today announced Ping Cao, Ph.D., CEO and co-founder, will give a presentation at the 3rd Annual Ligase Targeting Drug Development Summit on Thursday, April 13, 2023, at 9:00 a.m. ET in Boston, Massachusetts.

Boehringer Ingelheim announced today the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.

Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, announced the appointment of John Nicols to Chair its Board of Directors.

EvoEndo®, Inc., a medical device company developing platforms for Unsedated Transnasal Endoscopy, announced key leadership changes.

Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site, enabling that location to address customers’ workflow from early drug development through commercial manufacturing and underscoring the company’s commitment to helping clients get medicines to patients sooner.

DIACCURATE today announced that it has been selected to present new nonclinical efficacy and clinical exploratory correlative analyses of its lead compound DIACC3010 in metastatic ER+ HER2- breast cancer in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.